Search Result

Results for "

CLKs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (1) Apoptosis (3) Autophagy (1) Casein Kinase (3) CDK (40) Cryptochrome (1) DYRK (17) Dystrophin (1) GSK-3 (6) Haspin Kinase (2) IRAK (1) MELK (2) mTOR (2) Parasite (1) Pim (2) Reactive Oxygen Species (ROS) (1) RET (3) Ribosomal S6 Kinase (RSK) (2) RIP kinase (2) Small Interfering RNA (siRNA) (12) SRPK (1) STK33 (3) TNF Receptor (1) VEGFR (1) Wnt (2)
By Research Areas:	Cancer (35) Infection (5) Inflammation/Immunology (4) Metabolic Disease (4) Neurological Disease (5)
Oligonucleotides:	Rat Pre-designed siRNA Sets (4) Mouse Pre-designed siRNA Sets (4) Human Pre-designed siRNA Sets (4) siRNAs (12)

Inhibitors & Agonists

Peptides

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131978

DB18	CDK	Cancer
DB18 is a potent and selective inhibitor of CDC2-like kinases (CLKs), with IC₅₀ values in the range of 10-30 nM for CLK1, CLK2 and CLK4. DB18 has anti-tumor activity .

HY-115470

CLK-IN-T3 1 Publications Verification	CDK DYRK	Cancer
CLK-IN-T3 is a high potent, selective, and stable CDC-like kinase (CLK) inhibitor with IC₅₀s of 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases, respectively. CLK-IN-T3 has anti-cancer activity .

HY-137435

Cirtuvivint 1 Publications Verification SM08502	CDK	Cancer
Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research .

HY-144875

Rogocekib CTX-712	CDK	Cancer
Rogocekib is an orally effective CLK 2 inhibitor, with an IC₅₀ of 1.4 nM, showing anti-tumor activity .

HY-113825

CLK1/2-IN-1	CDK	Cancer
CLK1/2-IN-2 is *CLK1* and *CLK2* inhibitor with IC₅₀ values of 16 nM and 45 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities ^{[1] ^.}

HY-176885

CDD-2211	STK33 RET	Others
CDD-2211 is a STK33 inhibitor, with a K_d of 0.018 nM and an IC₅₀ of 5 nM. CDD-2211 has relatively weak inhibitory effects on off-target kinases, with IC₅₀ values of 115 nM for *CLK1, 48 nM for CLK2, 187 nM for CLK4, and 78 nM for RET*. CDD-2211 can be used for the study of contraception .

HY-176884

CDD-2110	STK33 RET	Others
CDD-2210 is a STK33 inhibitor, with a K_d of 0.1 nM and an IC₅₀ of 38 nM. CDD-2210 has relatively weak inhibitory effects on off-target kinases, with IC₅₀ values of 1209 nM for *CLK1, 917 nM for CLK2, 544 nM for CLK4, and 746 nM for RET*. CDD-2210 can be used for the study of contraception .

HY-176885A

CDD-2212	STK33 RET	Others
CDD-2212 is a STK33 inhibitor, with a K_d of 1.9 nM and an IC₅₀ of 999 nM. CDD-2212 has relatively weak inhibitory effects on off-target kinases, with IC₅₀ values of 3223 nM for *CLK1, 1555 nM for CLK2, 5884 nM for CLK4, and 1093 nM for RET*. CDD-2212 can be used for the study of contraception .

HY-157995

Dyrk1A-IN-7	DYRK	Metabolic Disease Inflammation/Immunology Cancer
Dyrk1a-in-7 (Compound 29) is a selective DYRK1A kinase inhibitor, and has good kinase selectivity for CLK1 kinase. The IC₅₀ value of DYRK1A is 28 nM. For CLK2, K_d is 17.5 nM. Dyrk1a-in-7 can be used in the research of cancer, type Ⅱ diabetes and neurological diseases .

HY-173510

CLK2/3-IN-1	CDK	Cancer
CLK2/3-IN-1 (Compound 7c) is an orally active *CLK2/3* inhibitor (EC₅₀: 5.07 nM and 30.03 nM, respectively). CLK2/3-IN-1 binds to Lys193 and Lys186 of CLK2/3 via hydrogen bonds. CLK2/3-IN-1 can inhibit the proliferation of SW480 tumor cells (IC₅₀: 163 nM). CLK2/3-IN-1 can be used to study CLK-related tumor diseases .

HY-152219

CLK1-IN-2	CDK	Infection Cancer
CLK1-IN-2 is metabolically stable *Clk1* inhibitor. CLK1-IN-2 has selectivity for Clk1 with an IC₅₀ value of 1.7 nM. CLK1-IN-2 can be used for the research of tumour, Duchenne's muscular dystrophy and viral infections such as HIV-1 and influenza .

HY-149262

CLK1-IN-3	CDK DYRK Autophagy	Cancer
CLK1-IN-3 (compound 10ad) is a potent and selective *Clk1* inhibitor, with an IC₅₀ of 5 nM and over 300-fold selectivity for Dyrk1A. CLK1-IN-3 also shows a relatively potent inhibition against *Clk2* and *Clk4, with IC₅₀* values of 42 and 108 nM, respectively. CLK1-IN-3 potently induces autophagy in vitro. CLK1-IN-3 can be used for acute liver injury (ALI) research .

HY-113670

CLK1/2-IN-2	CDK	Cancer
CLK1/2-IN-2 is *CLK1* and *CLK2* inhibitor with IC₅₀ values of 1.1 nM and 2.4 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities ^{[1] ^.}

HY-123600

SRI-29329	CDK	Others
SRI-29329 is a specific *CLK* inhibitor, with IC₅₀ values of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively .

HY-146335

CLK1/4-IN-1	CDK	Cancer
CLK1/4-IN-1 (compound 31) is a potent and selective *Clk1* and *Clk4* inhibitor with an IC₅₀ value of 9.7 nM and 6.6 nM, respectively. CLK1/4-IN-1 has growth inhibitory activities against T24 cancer cells with GI₅₀ of 1.1 μM. CLK1/4-IN-1 can be used for researching anticancer .

HY-15338

TG003 Maximum Cited Publications 7 Publications Verification	CDK	Cancer
TG003 is a potent inhibitor of *Clk1/Sty; inhibits Clk1 and Clk4 with IC₅₀* values of 20 and 15 nM, respectively .

HY-400528

CLK1-IN-4	CDK	Inflammation/Immunology
CLK1-IN-4 (Compound 79) is an inhibitor for CDC like kinase 1 (CLK-1) with IC₅₀ of 1.5-2 μM .

HY-E70692

CLK3 Recombinant Human Active Protein Kinase	CDK	Cancer
CLK3 is a nuclear dual-specificity kinase has been shown to undergo conserved alternative splicing to generate catalytically active (Clk) and inactive (ClkT) isoforms. CLK3 Recombinant Human Active Protein Kinase is a recombinant CLK3 protein that can be used to study CLK3-related functions .

HY-153708

*SGC-CLK-1* CAF-170	CDK	Cancer
SGC-CLK-1, a chemical probe, is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. SGC-CLK-1 can inhibit the growth of melanoma and glioblastoma cells .

HY-113831

CLK1/2-IN-3	CDK SRPK	Cancer
LK1/2-IN-3 (compound 3) is a potent and selective *CLK1* and *CLK2* inhibitor with IC₅₀ values of 1.1, 2.1, 130, 260, 260 nM for CLK1, CLK2, SRPK1, SRPK2, SRPK3, respectively. CLK1/2-IN-3 shows anti-proliferative activity. CLK1/2-IN-3 reduces the levels of endogenous phosphorylated SR proteins and increases the expression of S6K mRNAs .

HY-117049

Leucettine L41 1 Publications Verification	DYRK CDK GSK-3 Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease
Leucettine L41 is a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) and CDC-like kinases (CLKs). Leucettine L41 can also inhibit GSK-3 singnaling. Leucettine L41 can inhibit cell apoptosis and ROS production. Leucettine L41 can promote β-cell cell cycle progression, cell proliferation and increase insulin secretion. Leucettine L41 can be used for the researches of neurological disease and metabolic disease, such as Alzheimer’s disease (AD) and diabetes .

HY-103082

CLK1-IN-1 1 Publications Verification	CDK	Others
CLK1-IN-1 is a potent and selective of Cdc2-like kinase 1 (CLK1) inhibitor, with an IC₅₀ of 2 nM.

HY-130676

CLK-IN-T3N	CDK	Cancer
CLK-IN-T3N, the negative control of CLK-IN-T3 (HY-115470), is a chemical probe for CDC-like kinase (CLK).

HY-E70691

CLK1 Recombinant Human Active Protein Kinase	CDK	Cancer
CLK1 is one of the dual specificity kinases and is the founding member of the 'LAMMER' family of kinases. CLK1 activity is positively regulated by phosphorylation on either tyrosine residues or serine/threonine residues, and is negatively regulated by steric constraints mediated by the N-terminal domain, as well as, by phosphorylation on a subset of serine/threonine residues within the catalytic domain. CLK1 Recombinant Human Active Protein Kinase is a recombinant CLK1 protein that can be used to study CLK1-related functions .

HY-15951

ML167 CID44968231; NCGC00188654	CDK DYRK	Cancer
ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC₅₀ of 136 nM, >10-fold selectivity for closely related kinases Clk1, Clk2, Clk3 and Dyrk1A/1B .

HY-15338A

(E/Z)-TG003	CDK	Cancer
(E/Z)-TG003 is a racemic compound of (Z)-TG003 and (E)-TG003. (Z)-TG003 is a potent inhibitor of *Clk1/Sty; inhibits Clk1 and Clk4 with IC₅₀* values of 20 and 15 nM, respectively .

HY-125202

KuWal151	CDK DYRK	Cancer
KuWal151 is a CLK1, CLK2 and CLK4 inhibitor with a high selectivity margin towards DYRK kinases. KuWal151 has potent antiproliferative activity in an array of cultured cancer cell lines .

HY-12828A

KH-CB20	CDK DYRK	Infection Neurological Disease
KH-CB20, an E/Z mixture, is a potent and selective inhibitor of *CLK1* and the closely related isoform *CLK4, with an IC₅₀* of 16.5 nM for *CLK1. KH-CB20 can also inhibit DYRK1A* (IC₅₀=57.8 nM) and *CLK3* (IC₅₀=488 nM) .

HY-155723

Leucettinib-92	CDK DYRK	Others
Leucettinib-92 (compound 92) is an inhibitor of DYRK/CLK kinase, The IC₅₀s are 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM (CLK3), 124 nM (DYRK1A), 204 nM (DYRK1B), 0.16 μM (DYRK2), respectively. 1.0 μM (DYRK3), 0.52 μM (DYRK4), 2.78 μM (GSK3) .

HY-112296

T025 3 Publications Verification	CDK Apoptosis DYRK	Cancer
T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with K_d values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC₅₀ values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research .

HY-137443

Ipivivint 1 Publications Verification	CDK Wnt	Cancer
Ipivivint (Compound 38) is an orally active and potent CDC-like kinase (CLK) inhibitor with EC₅₀ of 1 nM and 7 nM for CLK2 (human) and CLK3 (human), respectively. Ipivivint also inhibits the Wnt pathway (EC50=13 nM) and tyrosine phosphorylation-regulated kinase 1A (human) (EC₅₀=5 nM) .

HY-RS16769

Clk2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Clk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Clk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Clk2 Mouse Pre-designed siRNA Set A Clk2 Mouse Pre-designed siRNA Set A

HY-RS17487

Clk4 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Clk4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Clk4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Clk4 Mouse Pre-designed siRNA Set A Clk4 Mouse Pre-designed siRNA Set A

HY-RS02819

CLK4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CLK4 Human Pre-designed siRNA Set A contains three designed siRNAs for CLK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CLK4 Human Pre-designed siRNA Set A CLK4 Human Pre-designed siRNA Set A

HY-RS02817

CLK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CLK2 Human Pre-designed siRNA Set A contains three designed siRNAs for CLK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CLK2 Human Pre-designed siRNA Set A CLK2 Human Pre-designed siRNA Set A

HY-RS02814

CLK1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CLK1 Human Pre-designed siRNA Set A contains three designed siRNAs for CLK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CLK1 Human Pre-designed siRNA Set A CLK1 Human Pre-designed siRNA Set A

HY-RS02816

Clk1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Clk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Clk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Clk1 Rat Pre-designed siRNA Set A Clk1 Rat Pre-designed siRNA Set A

HY-RS23209

Clk2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Clk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Clk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Clk2 Rat Pre-designed siRNA Set A Clk2 Rat Pre-designed siRNA Set A

HY-RS23945

Clk4 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Clk4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Clk4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Clk4 Rat Pre-designed siRNA Set A Clk4 Rat Pre-designed siRNA Set A

HY-RS02815

Clk1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Clk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Clk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Clk1 Mouse Pre-designed siRNA Set A Clk1 Mouse Pre-designed siRNA Set A

HY-RS16964

Clk3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Clk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Clk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Clk3 Mouse Pre-designed siRNA Set A Clk3 Mouse Pre-designed siRNA Set A

HY-RS23407

Clk3 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Clk3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Clk3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Clk3 Rat Pre-designed siRNA Set A Clk3 Rat Pre-designed siRNA Set A

HY-RS02818

CLK3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CLK3 Human Pre-designed siRNA Set A contains three designed siRNAs for CLK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CLK3 Human Pre-designed siRNA Set A CLK3 Human Pre-designed siRNA Set A

HY-12828

KH-CB19	CDK	Infection Neurological Disease
KH-CB19 is a potent *CLK* (cdc2-like kinase) inhibitor (CLK1 IC₅₀=19.7 nM; CLK3 IC₅₀=530 nM). KH-CB19 shows antiviral activity and inhibits influenza virus replication (IC₅₀=13.6?μM) .

HY-148765

CLK8	Cryptochrome	Metabolic Disease Cancer
CLK8 is a potent and specific CLOCK inhibitor that can disrupt the interaction between CLOCK and BMAL1 and interfere with nuclear translocation of CLOCK. CLK8 can be used for the research of disorders associated with dampened circadian rhythms .

HY-108709

CC-671 1 Publications Verification	CDK	Cancer
CC-671 is a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor with IC₅₀s of 0.005 and 0.006 μM for TTK and CLK2, respectively.

HY-111379

EHT 5372	DYRK CDK GSK-3	Neurological Disease Metabolic Disease Cancer
EHT 5372 is a highly potent and selective inhibitor of DYRK's family kinases with IC₅₀s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively .

HY-125290

MU1210	CDK DYRK	Cancer
MU1210 (compound 12f), a chemical probe, is an inhibitor of CDC-like kinases *Clk1, Clk2, and Clk4* (with IC₅₀ values of 8, 20, and 12 nM respectively), with IC₅₀ for HIPK1 and DYRK2 are 187 and 1309 nM. MU1210 also has favorable pharmacokinetic characteristics (in mice, 10 mg/kg, intraperitoneal injection: C_max=1.24 μM, T_1/2=58 minutes; no acute toxicity observed) .

HY-103647

K00546	CDK VEGFR GSK-3	Cancer
K00546 is a potent CDK1 and CDK2 inhibitor with IC₅₀s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. K00546 is also a potent CDC2-like kinase 1 (CLK1) and *CLK3* inhibitor with IC₅₀s of 8.9 nM and 29.2 nM, respectively .

HY-159963

PfCLK3-IN-1	Parasite	Infection
PfCLK3-IN-1 (Compound 4) is a covalent inhibitor for Plasmodium falciparum *CLK3* (Pf CLK3) under alkaline conditions with an pEC₅₀ of 7.1. PfCLK3-IN-1 reduces mature gametocytes in sexual stage parasites, and prevents transmission. PfCLK3-IN-1 inhibits P. falciparum Dd2-B2 clone with an IC₅₀ of 239.5 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks